Shenzhen Kangtai Biological Products Co., Ltd.
Symbol: 300601.SZ
SHZ
22.57
CNYMarktpreis heute
33.5591
P/E-Verhältnis
0.2598
PEG-Verhältnis
24.02B
MRK Kapital
- 0.01%
DIV Rendite
Shenzhen Kangtai Biological Products Co., Ltd. (300601-SZ) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 1758.9 | 1458.4 | 3549.5 | ||||||||||||
balance-sheet.row.short-term-investments | 0 | 563.4 | 440.8 | 725.6 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 2819.2 | 2414.7 | 1991.2 | ||||||||||||
balance-sheet.row.inventory | 0 | 772.9 | 727.8 | 1058.2 | ||||||||||||
balance-sheet.row.other-current-assets | 0 | 45 | 573.9 | 741.7 | ||||||||||||
balance-sheet.row.total-current-assets | 0 | 5396 | 5174.9 | 7340.7 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 5756.9 | 5176.1 | 4116.4 | ||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 504.2 | 475.2 | 736.3 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 504.2 | 475.2 | 736.3 | ||||||||||||
balance-sheet.row.long-term-investments | 0 | 2696.2 | 2041.3 | 99.4 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 630.3 | 708.3 | 558.6 | ||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 101.7 | 210.6 | 1297.6 | ||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 9689.4 | 8611.5 | 6808.3 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 0 | 15085.4 | 13786.4 | 14149 | ||||||||||||
balance-sheet.row.account-payables | 0 | 791.2 | 434.1 | 708.2 | ||||||||||||
balance-sheet.row.short-term-debt | 0 | 174.3 | 273.7 | 800.1 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 25.9 | 173.4 | 98.2 | ||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 2372.2 | 2015.7 | 1938 | ||||||||||||
Deferred Revenue Non Current | 0 | 328.7 | 383.1 | 349.5 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 0 | 1757.1 | 1600.8 | 2.8 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 2463.6 | 2461.2 | 2364.1 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-liab | 0 | 5215 | 4801 | 4982.2 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 0 | 1116.9 | 1120.5 | 687.1 | ||||||||||||
balance-sheet.row.retained-earnings | 0 | 2216.7 | 1641.1 | 2435 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 3117.4 | 3036 | 2417.5 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 3090.6 | 3187.7 | 3627.1 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 9541.7 | 8985.3 | 9166.7 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 15085.4 | 13786.4 | 14149 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-equity | 0 | 9541.7 | 8985.3 | 9166.7 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||
Total Investments | 0 | 3259.6 | 440.8 | 99.4 | ||||||||||||
balance-sheet.row.total-debt | 0 | 2546.6 | 2289.4 | 2738.1 | ||||||||||||
balance-sheet.row.net-debt | 0 | 1351 | 1271.7 | -811.4 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -132.7 | 1263.4 | 679.2 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 200.9 | 404.7 | 92.9 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | -205.5 | 50.7 | 93.2 | |||||||||||
cash-flows.row.stock-based-compensation | 0 | 10 | 30 | 104.8 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | -604.5 | -275.6 | -461.7 | |||||||||||
cash-flows.row.account-receivables | 0 | -488.8 | 273.9 | -796.5 | |||||||||||
cash-flows.row.inventory | 0 | 220.7 | -746.7 | -209.7 | |||||||||||
cash-flows.row.account-payables | 0 | -131 | 146.5 | 451.3 | |||||||||||
cash-flows.row.other-working-capital | 0 | -205.5 | 50.7 | 93.2 | |||||||||||
cash-flows.row.other-non-cash-items | 0 | 1277.6 | 179.2 | -68.6 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -1310.4 | -2540.4 | -1226.7 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 0.1 | 0.2 | 1227.7 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | -3518 | -1100 | -2625 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 2224.4 | 2198.2 | 13.7 | |||||||||||
cash-flows.row.other-investing-activites | 0 | -2.4 | 1.7 | -1226.7 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -2606.3 | -1440.3 | -3836.9 | |||||||||||
cash-flows.row.debt-repayment | 0 | -1070.4 | -26.5 | -256 | |||||||||||
cash-flows.row.common-stock-issued | 0 | 132.7 | -2.1 | -1 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | -20.6 | 2.1 | -0.2 | |||||||||||
cash-flows.row.dividends-paid | 0 | -622.2 | -220.4 | -207.3 | |||||||||||
cash-flows.row.other-financing-activites | 0 | 1115.6 | 2699 | 4243.3 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -464.9 | 2452.2 | 3778.7 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -1.7 | -1 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 0 | -2527.1 | 2663.1 | 381.6 | |||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 994.1 | 3521.3 | 858.1 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 3521.3 | 858.1 | 476.5 | |||||||||||
cash-flows.row.operating-cash-flow | 0 | 545.7 | 1652.3 | 439.8 | |||||||||||
cash-flows.row.capital-expenditure | 0 | -1310.4 | -2540.4 | -1226.7 | |||||||||||
cash-flows.row.free-cash-flow | 0 | -764.7 | -888.1 | -786.8 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 3451.8 | 3157.4 | 3652.1 | ||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 622.8 | 499.9 | 986.4 | ||||||||||||
income-statement-row.row.gross-profit | 0 | 2829.1 | 2657.5 | 2665.7 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 0 | -118.8 | 74.4 | 73.9 | ||||||||||||
income-statement-row.row.operating-expenses | 0 | 2054.2 | 2020.8 | 1071.9 | ||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 2677 | 2520.8 | 2058.4 | ||||||||||||
income-statement-row.row.interest-income | 0 | 115.6 | 132.6 | 114.9 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 113.7 | 109 | 54.5 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 165.5 | -1085.3 | -13 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -118.8 | 74.4 | 73.9 | ||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 165.5 | -1085.3 | -13 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 113.7 | 109 | 54.5 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 240.7 | 200.9 | 676.6 | ||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | 0 | 774.8 | 747 | 1452.2 | ||||||||||||
income-statement-row.row.income-before-tax | 0 | 940.3 | -338.2 | 1439.2 | ||||||||||||
income-statement-row.row.income-tax-expense | 0 | 79 | -205.5 | 175.9 | ||||||||||||
income-statement-row.row.net-income | 0 | 861.3 | -132.7 | 1263.4 |
Häufig gestellte Frage
Wie hoch ist die Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) Gesamtvermögen?
Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) Gesamtvermögen ist 15085358535.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist N/A.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.832.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist 0.165.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist 0.224.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist 0.213.
Was ist der Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist 861303903.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 2546554090.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 2054244031.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 0.000.